Insmed Incorporated (INSM) Stock Analysis 2026

Insmed develops therapies for serious and rare respiratory diseases. Its marketed product Arikayce is an inhaled antibiotic for refractory Mycobacterium avium complex lung infection, delivered directly to the lungs via nebuliser. The larger value driver has been brensocatib, an oral therapy for non-cystic-fibrosis bronchiectasis — a condition with a substantial patient population and, historically, no approved treatment addressing the underlying inflammation.

This chart shows how Insmed's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Insmed Incorporated doesn't carry a meaningful trailing P/E right now, generates $-571.8M in free cash flow, runs a debt/equity ratio of 97.65, and converts shareholder equity into profit at a -87.2% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

Wall Street analysts covering Insmed Incorporated currently haven't converged on a clear consensus rating, with a mean 12-month price target of $197.74 (+105.4% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

We use 1 valuation model to estimate INSM's intrinsic value. Intrinsic value is what a stock is truly worth based on the company's fundamentals, independent of what the market prices it at today. If multiple models agree the stock is undervalued, that convergence is a stronger signal.

INSM is currently in a death cross pattern, trading below its 50-day average of $119.65 and below its 200-day average of $131.06. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.

INSM's investment case breaks down into 4 bull points and 4 bear points below. The bull case outlines the key reasons the stock could outperform — competitive advantages, growth catalysts, and market tailwinds. The bear case highlights the most significant risks. A strong bull case with manageable bear risks typically makes for a more compelling investment.

In-depth reports on companies operating alongside INSM — business models, bull and bear cases, and the metrics that matter.